Skip to main content

Pediatric Drug Development in Japan: A Comparison of the Current Situation and Characteristics Between Japan and Europe

Therapeutic Innovation & Regulatory Science volume 54, pages 1152–1158 (2020)Cite this article

Abstract

Background

In contrast to the European Union and the USA, no laws or regulations mandating pediatric drug development have been established in Japan. Based on the information on drugs approved for pediatric indications in Europe and Japan, we evaluated the recent status of pediatric drug approvals and their characteristics in Japan in comparison with those of Europe.

Methods

Drugs approved for pediatric indications between 2007 and 2015 in both regions were included in the study. The proportion of drugs with pediatric indications was calculated by the Anatomical Therapeutic Chemical (ATC) classification, and the status of pediatric formulation development was examined. The time from adult to pediatric indication approval was determined.

Results

A total of 135 drugs were approved for pediatric indications in Europe, with 208 approved in Japan. The proportion of drugs with pediatric indications in Japan among those approved for pediatric indications in Europe was lower among those with ATC classifications of N (Nervous system) and J (Antiinfectives for systemic use) and those with the development of pediatric formulations than among others. Excepting drugs for which adult and pediatric indications were simultaneously approved, the most commonly observed period from the adult indication approval to the pediatric indication approval was more than 12 years in Japan and 3–6 years in Europe.

Conclusion

The present findings suggested that pediatric development is indeed being promoted in Japan. However, the period from adult to pediatric indication approval was longer in Japan than in Europe, and the development of pediatric drugs for certain diseases has been sluggish, indicating room for further improvement.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Figure 1.
Figure 2.

References

  1. Richey RH, Shah UU, Peak M, et al. Manipulation of drugs to achieve the required dose is intrinsic to paediatric practice but is not supported by guidelines or evidence. BMC Pediatr. 2013;13:81.

    Article  Google Scholar 

  2. Ministry of Health, Labour and Welfare. Clinical Investigation of Medicinal Products in the Pediatric Population (ICH E11) (Notification No. 1334 of the Evaluating and Licensing Division, PMSB dated December 15, 2000) [in Japanese] https://www.pmda.go.jp/files/000156072.pdf. Accessed 18 Jan 2020.

  3. Ministry of Health, Labour and Welfare. Addendum to ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population (ICH E11(R1)) (Notification No. 1227-(5) of the Pharmaceutical Evaluation Division, PSEHB dated December 27, 2017) [in Japanese] https://www.pmda.go.jp/files/000222107.pdf. Accessed 18 Jan 2020.

  4. Saint Raymond A. Regulatory aspects of drug development in children: change and resistance to change. Expert Rev Clin Pharmacol. 2010;3:593–5.

    Article  Google Scholar 

  5. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 18 Jan 2020.

  6. State of Paediatric Medicines in the EU 10 years of the EU Paediatric Regulation: Report from the Commission to the European Parliament and the Council COM (2017) 626. http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2017/0626/COM_COM(2017)0626_EN.pdf. Accessed 18 Jan 2020.

  7. Baum VC, Bax R, Heon D, Yang Z, Sakiyama M. Pediatric drug regulation: international perspectives. Paediatr Anaesth. 2019;29:572–82.

    Article  Google Scholar 

  8. Mulberg AE, Murphy D, Dunne J, Mathis LL. Pediatric drug development: concepts and applications. 2nd ed. Singapore: Wiley; 2013. p. 170–6.

    Book  Google Scholar 

  9. Ministry of Health, Labour and Welfare. Evaluation committee on unapproved or off-label drugs with high medical needs [in Japanese]. https://www.mhlw.go.jp/stf/shingi/other-iyaku_128701.html. Accessed 18 Jan 2020.

  10. Tsukamoto K, Carroll KA, Onishi T, Matsumaru N, Brasseur D, Nakamura H. Improvement of pediatric drug development: regulatory and practical frameworks. Clin Ther. 2016;38:574–81.

    Article  Google Scholar 

  11. Annex 10-year Report to the European Commission, 15 November 2016, EMA/35987/2016. https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_annex.pdf. Accessed 18 Jan 2020.

  12. Pharmaceuticals and Medical Devices Agency. List of approved new products [in Japanese]. https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0010.html. Accessed 18 Jan 2020.

  13. Strickley RG. Pediatric oral formulations: an updated review of commercially available pediatric oral formulations since 2007. J Pharm Sci. 2019;108:1335–65.

    Article  CAS  Google Scholar 

  14. ATC/DDD index 2019. WHO Collaborating Centre for drug statistics methodology. http://www.whocc.no/atcddd/indexdatabase/. Updated December 13, 2018. Accessed 18 Jan 2020.

  15. Hudgins JD, Bacho MA, Olsen KL, Bourgeois FT. Pediatric drug information available at the time of new drug approvals: a cross-sectional analysis. Pharmacoepidemiol Drug Saf. 2018;27:161–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan

    Eiji Ueyama MS, Masayuki Kaneko PhD & Mamoru Narukawa PhD

  2. Development, Astellas Pharma Inc, Tokyo, Japan

    Eiji Ueyama MS

Authors
  1. Eiji Ueyama MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masayuki Kaneko PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mamoru Narukawa PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eiji Ueyama MS.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ueyama, E., Kaneko, M. & Narukawa, M. Pediatric Drug Development in Japan: A Comparison of the Current Situation and Characteristics Between Japan and Europe. Ther Innov Regul Sci 54, 1152–1158 (2020). https://doi.org/10.1007/s43441-020-00136-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s43441-020-00136-0

Keywords

  • Pediatric drug development
  • Regulatory science
  • Development strategy
  • Legislation
  • Incentive